Currently, early screening and monitoring of CRC rely on conventional tumor markers including fecal occult blood (FOB), fecal transferrin (TRF), carcinoembryonic antigen (CEA), and carbohydrate antigen 19‐9 (CA19‐9).6, 7, 8. This evidence concerns the gene TF and colorectal carcinoma.